SCHEMBL7937799

SCHEMBL7937799

FC(F)(F)c1nc2ccccc2nc1/C=C/c1nc(Cl)cc(N2CCCC2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 8/20 0.44
HRH4 Q9H3N8 1/20 0.38
KDM4E B2RXH2 3/20 0.36
GAA P10253 2/20 0.36
TP53 P04637 2/20 0.36
HTT P42858 1/20 0.36
MAPT P10636 3/20 0.36
ACHE P22303 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TLR7 Q9NYK1 1/20 0.35
RXFP1 Q9HBX9 2/20 0.35
CASP1 P29466 2/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
CASP7 P55210 1/20 0.35
GFER P55789 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7942725 0.83 PDE10A (0.61) PDE10AKDM4EGAATP53HTT
SCHEMBL7931201 0.80 PDE10A (0.48) PDE10AHRH4KDM4EGAATP53
SCHEMBL2023576 0.80 PDE10A (0.63) PDE10AKDM4EGAATP53HTT
SCHEMBL2023575 0.80 PDE10A (0.63) PDE10AKDM4EGAATP53HTT
SCHEMBL7940301 0.80 PDE10A (0.46) PDE10AKDM4EGAATP53HTT
SCHEMBL7936485 0.80 PDE10A (0.48) PDE10AKDM4EGAATP53HTT
SCHEMBL7937680 0.79 PDE10A (0.55) PDE10AKDM4EGAATP53HTT
SCHEMBL7942719 0.78 PDE10A (0.56) PDE10AKDM4EGAATP53HTT
SCHEMBL7934257 0.78 PDE10A (0.50) PDE10AHRH4KDM4EGAACASP1
SCHEMBL7931205 0.78 PDE10A (0.46) PDE10AHRH4KDM4EGAAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-06-30 US disclosed
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-06-30 US disclosed
WO-2010027097-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE10A, PDE12, PDE9A PDE10A 1/4885HRH4 877/4885KDM4E 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.